Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension

Expert Review of Ophthalmology

Volumn 4, Issue 2, 2009, Pages 129-133

  Holló, Gábor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Brinzolamide timolol fixed combination; Ocular hypertension; Open angle glaucoma; Ophthalmic suspension

Indexed keywords

ANTIGLAUCOMA AGENT; AZARGA; BRINZOLAMIDE; BRINZOLAMIDE PLUS TIMOLOL; CARBOMER; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST PLUS TIMOLOL; POLYMER; PROSTAGLANDIN DERIVATIVE; TIMOLOL MALEATE; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; BLOOD PRESSURE; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; EYE DISCOMFORT; EYE IRRITATION; FALLING; HEART FAILURE; HUMAN; INTRAOCULAR HYPERTENSION; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PUNCTATE KERATITIS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SYNCOPE;

EID: 68149164508     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.09.7     Document Type: Article

References (23)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90(3), 262-267 (2006).
2. The Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 122(4), 532-538 (2004).
3. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd Edition. DOGMA srl, Italy (2008)
4. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypertensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120(6), 701-713 (2002).
5. The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS) 7: the relationship between the control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130(10), 429-440 (2000).
6. Heijl A, Leske MC, Bengtsson B et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120(10), 1268-1279 (2002).
7. Robin A, Novack GD, Covert DV et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am. J. Ophthalmol. 144(10), 533-540 (2007).
8. Baudouin C, Liang H, Hamard P et al. The ocular surface of glaucoma patients treated over the long-term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 115(1), 109-115 (2008).
9. Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 20(12), 919-947 (2003).
10. Iester M. Brinzolamide. Expert Opin. Pharmacother. 9(4), 1-10 (2008).
11. Holló G. Use of topical carbonic anhydrase inhibition in glaucoma treatment. In: Pharmacotherapy in Glaucoma. Orgül S, Flammer J (Eds). Hans Huber Verlag, Switzerland, 145-152 (2000).
12. Holló G. Carbonic anhydrase inhibitors. In: Glaucoma. Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG (Eds). Saunders, UK (2009) (In press).
13. Bron AJ, Chidlow G, Melena J et al. β blockers in the treatment of glaucoma. In: Pharmacotherapy in Glaucoma. Orgül S, Flammer J (Eds). Hans Huber Verlag, Switzerland, 79-113 (2000).
14. Kaback M, Scoper SV, Arzeno G et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 115(10), 1728-1734 (2008).
15. Manni G, Denis P, Chew P et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2% timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma (2009) (Epub ahead of print).
16. Holló G, Chiselita D, Petkova N et al. The efficacy and safety of timolol maleate 0.5% versus brinzolamide 1% each given twice daily added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma. Eur. J. Ophthalmol. 16(6), 816-823 (2006).
17. Holló G, Kóthy P. Intraocular pressure reduction with travoprost/timolol, with and without adjunctive brinzolamide, in glaucoma. Curr. Med. Res. Opin. 24(6), 1755-1761 (2008).
18. Tsukamoto H, Noma H, Matsuyama S et al. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a β-blocker in patients with glaucoma. J. Ocul. Pharmacol. Therap. 21(2), 170-173 (2005).
19. Siesky B, Harris A, Cantor LB et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br. J. Ophthalmol. 92(4), 500-504 (2008).
20. Siesky B, Harris A, Brizendine E et al. Literature review and meta-ana lysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv. Ophthalmol. 54(1), 33-46 (2009).
21. Vold SD, Evans RM, Stewart RH et al. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination to BIDdosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J. Ocular Pharmacol. Ther. 24(6), 601-628 (2008).
22. Mundorf TK, Rauchman SH, Williams RD et al. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin. Ophthalmol. 2(3), 623-628 (2008).
23. Kanner E, Tsai JC. Glaucoma medications: use and safety in the elderly population. Drugs Aging 23(4), 321-332 (2006).